Physician profile
Kavitha Waggoner
NPI 1275821191
$2,656.91
in general payments reported to CMS, 2019-2025
19 companies · $327 in 2025
The $327 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $229 · 2021: $495 · 2022: $688 · 2023: $593 · 2024: $324 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $854.45 | 2020-2025 | Skyrizi, Linzess, Viberzi |
| Celgene Corporation | $346.73 | 2021-2024 | Zeposia |
| Pfizer INC. | $309.44 | 2022-2025 | |
| Gilead Sciences, INC. | $211.82 | 2020-2023 | |
| Nestle Healthcare Nutrition INC. | $188.30 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $126.79 | 2021-2025 | Entyvio |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2021 | |
| Intercept Pharmaceuticals, INC. | $99.09 | 2023 | Ocaliva |
| Janssen Biotech, INC. | $76.47 | 2022-2025 | Tremfya |
| Ironwood Pharmaceuticals, INC | $65.57 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.67 | 2020-2023 | Trulance |
| Genzyme Corporation | $54.30 | 2023-2024 | |
| Alfasigma USA, INC. | $31.63 | 2020 | |
| Ardelyx, INC. | $29.30 | 2022 | |
| Medtronic, INC. | $23.90 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $16.49 | 2020 | |
| Capsovision, INC. | $13.15 | 2023 | Capsocam Plus |
| Ferring Pharmaceuticals INC. | $12.92 | 2021 | |
| Braintree Laboratories, INC. | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kavitha Waggoner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.